China Medical System
867 · HKEX
Public Market Listing
Live quotes, historical charts, and market capitalization for China Medical System are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(9 total)
| Target & Modality | |||
|---|---|---|---|
Benzgalantamine(Zunveyl) | Approved | Acetylcholinesterase/nicotinic receptor (prodrug)Small molecule | Alzheimer's Disease |
| Approved | VEGF-AAntibody fragment | Age-Related Macular DegenerationDiabetic Macular Edema Wet Age-Related Macular Degeneration | |
Ferric derisomaltose(Monoferric / Monofer) | Approved | Iron repletionOther | Heart FailureChronic Kidney DiseaseIron Deficiency Anemia |
Sucroferric oxyhydroxide(Velphoro) | Approved | Dietary phosphateSmall molecule | Chronic Kidney DiseaseHyperphosphatemia |
tildrakizumab(Ilumya) | Approved | IL-23 p19Monoclonal antibody | Psoriatic ArthritisPsoriasis |
Desidustat(Oxemia) | Phase 3 | HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule | Chronic Kidney Disease |
| Phase 3 | Adenosine A3 receptor | MASH / NASHHepatocellular Carcinoma | |
| Phase 3 | Adenosine A3 receptorSmall molecule | Psoriasis | |
| Phase 2/3 | TYK2Small molecule | Atopic DermatitisPsoriasis |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (5)
January 2027 (1)
April 2027 (1)
What to watch
August 2027 (1)
What to watch
2028 (2)
February 2028 (1)
December 2028 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.1B | $81M | — | — | report ↗ |